Whoop has announced a new biomarker panel specifically for women that broadens the scope of its Advanced Labs blood test analysis, as well as an updated suite of dynamic cycle insights.

Launching in the US in April, the new ‘Women’s Health Specialized Blood Biomarker Panel’ adds 11 clinically-backed biomarkers to the existing baseline testing suite.

These include Anti-Müllerian Hormone (AMH) for ovarian reserve, Progesterone, and Thyroid Peroxidase Antibodies (TPOAb), as well as markers of nutrient sufficiency such as Vitamin B12 and Folate.

The goal, the brand says, is to provide a clearer picture of life stages that are often misinterpreted by traditional testing, such as perimenopause and thyroid dysfunction.

Crucially, the lab data fed into this wider Advanced Labs set is no longer a static snapshot, either. Whoop says it will integrate these results with its continuous metrics to provide cycle-aware biomarker ranges.

So, when a member completes a blood draw, the app automatically adjusts the ‘optimal’ or ‘out of range’ benchmarks based on exactly where the user is in their menstrual cycle, ensuring the data is viewed through a lens of shifting hormonal levels.

Cycle insights get dynamic

The platform is also receiving a ‘Hormonal Symptom Insights’ and ‘Predictions’ update, adding to the existing menstrual cycle and pregnancy insights.

Rather than just simple logging, the system can now harness historical data to anticipate when symptoms are likely to occur. This includes a dynamic date window for the next period, as well as trends in cycle length, variability, and period length.

The hope, Whoop says, is to flag irregular patterns earlier to avoid prolonged issues, and also to allow users to adjust their training and recovery plans in advance. And it’s all backed up by a new Menstrual Cycle White Paper, which details how the company’s algorithms account for variable cycles and hormonal birth control.

The Wareable take

Similar to what we’ve seen from brands like Oura—which itself launched an AI model trained on women’s health studies in February—Whoop’s latest move here is an attempt to deliver for a demographic that’s been critically underserved in research and dedicated health features.

By combining more focused insights via its blood work platform with its daily metrics, the company is taking another significant step towards being a comprehensive health platform.

However, with the panel being a US-exclusive launch for now, international users will have to wait to see if this latest round of dynamic, targeted insights can successfully turn more information into more action.

Similar to what we saw last year with the protracted worldwide rollout for Advanced Labs, we expect the women-focused biomarker panel to go global at some point in 2026. For now, though, stay tuned.